Key Adverse Events Following Childhood Cancer
S
Sandeep Batra, MD
Primary Investigator
Enrolling By Invitation
21 years and younger
All
Phase
N/A
3 Locations
Brief description of study
What is the purpose of this study?
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. The goal of this study is to identify subjects who are more likely to develop a late-occurring complication(s) after undergoing treatment for childhood cancer.
THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office
Email: iutrials@iu.edu
Phone: (317) 278-5632
Detailed description of study
What will happen during the study?
- The purpose of this study is to identify key adverse events developing in patients (cases) with a primary cancer diagnosed at age 21 or younger.
- DNA and RNA from peripheral blood or saliva sample of patients is analyzed for the presence of polymorphisms in genes associated with an increased risk of late-occurring complications.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Childhood Malignant Neoplasm, Riley
-
Age: - 21 Years
-
Gender: All
Inclusion Criteria
- Diagnosis of primary cancer at age 21 or younger
- In active follow-up by a Children's Oncology Group (COG) institution
- Development of one of the following key adverse events after initiation of prior cancer therapy:Cardiac dysfunction, Myocardial infarction, Ischemic stroke, Avascular necrosis, Subsequent malignant neoplasm
Exclusion Criteria
- Prior allogeneic (non-autologous) hematopoietic cell transplant
Updated on
12 Sep 2024.
Study ID: 1011003233, PHO-COG-FALLON-ALTE03N1, NCT00082745
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
